Skip to main content
    M

    Merck & Company Inc (MRK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $145.35
    -2.02 (-1.37%)

    Market Cap: $363.59B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    92%(36/39)
    Avg Surprise
    +11.65%
    Streak
    20 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$2.13
    Range$1.80 - $2.29
    18 analysts
    EPS RevisionsNo revisions (7d)
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$2.30-7.6%
    60d ago$2.22-4.1%
    30d ago$2.21-3.8%
    7d ago$2.19-2.7%
    Current$2.13
    Revenue Consensus
    $17.3B
    Range$16.9B - $17.5B
    16 analysts
    Period ending Dec 31, 2026
    EPS Consensus$2.29
    Range$2.11 - $2.41
    26 analysts
    Revenue Consensus
    $17.5B
    Range$16.9B - $17.9B
    24 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$2.29---
    Sep 26EST
    		-$2.13---
    Jun 26
    Reported Aug 4
    		$-0.13$-0.26+50.00%Beat-106.1%
    Mar 26
    Reported Apr 30
    		$-1.28$-1.47+12.93%Beat-157.7%
    Dec 25
    Reported Feb 3
    		$2.04$2.01+1.49%Beat+18.6%
    Sep 25
    Reported Oct 30
    		$2.58$2.35+9.79%Beat+64.3%
    Jun 25
    Reported Jul 29
    		$2.13$2.03+4.93%Beat-6.6%
    Mar 25
    Reported Apr 24
    		$2.22$2.14+3.74%Beat+7.2%
    Dec 24
    Reported Feb 4
    		$1.72$1.67+2.99%Beat+5633.3%
    Sep 24
    Reported Oct 31
    		$1.57$1.57+0.00%Beat-26.3%
    Jun 24
    Reported Jul 30
    		$2.28$2.14+6.54%Beat+210.7%
    Mar 24
    Reported Apr 25
    		$2.07$1.92+7.81%Beat+47.9%
    Dec 23
    Reported Feb 1
    		$0.03N/A+127.27%Beat-98.1%
    Sep 23
    Reported Oct 26
    		$2.13$1.95+9.23%Beat+15.1%
    Jun 23
    Reported Aug 1
    		$-2.06$-2.18+5.50%Beat-210.2%
    Mar 23
    Reported Apr 27
    		$1.40$1.34+4.48%Beat-34.6%
    Dec 22
    Reported Feb 2
    		$1.62$1.54+5.19%Beat-10.0%
    Sep 22
    Reported Oct 27
    		$1.85$1.71+8.19%Beat+5.7%
    Jun 22
    Reported Jul 28
    		$1.87$1.71+9.36%Beat+42.7%
    Mar 22
    Reported Apr 28
    		$2.14$1.83+16.94%Beat+52.9%
    Dec 21
    Reported Feb 3
    		$1.80$1.52+18.42%Beat+36.4%
    Sep 21
    Reported Oct 28
    		$1.75$1.55+12.90%Beat+0.6%
    Jun 21
    Reported Jul 29
    		$1.31$1.35-2.96%Miss-4.4%
    Mar 21
    Reported Apr 29
    		$1.40$1.61-13.04%Miss-6.7%
    Dec 20
    Reported Feb 4
    		$1.32$1.39-5.04%Miss+13.8%
    Sep 20
    Reported Oct 27
    		$1.74$1.43+21.68%Beat+15.2%
    Jun 20
    Reported Jul 31
    		$1.37$1.09+25.69%Beat+5.4%
    Mar 20
    Reported Apr 28
    		$1.50$1.34+11.94%Beat+23.0%
    Dec 19
    Reported Feb 5
    		$1.16$1.15+0.87%Beat+11.5%
    Sep 19
    Reported Oct 29
    		$1.51$1.24+21.77%Beat+26.9%
    Jun 19
    Reported Jul 30
    		$1.30$1.16+12.07%Beat+22.6%
    Mar 19
    Reported Apr 30
    		$1.22$1.05+16.19%Beat+16.2%
    Dec 18
    Reported Feb 1
    		$1.04$1.03+0.97%Beat+6.1%
    Sep 18
    Reported Oct 25
    		$1.19$1.14+4.39%Beat+7.2%
    Jun 18
    Reported Jul 27
    		$1.06$1.03+2.91%Beat+5.0%
    Mar 18
    Reported May 1
    		$1.05$1.00+5.00%Beat+19.3%
    Dec 17
    Reported Feb 2
    		$0.98$0.94+4.26%Beat+10.1%
    Sep 17
    Reported Oct 27
    		$1.11$1.03+7.77%Beat-
    Jun 17
    Reported Jul 28
    		$1.01$0.87+16.09%Beat-
    Mar 17
    Reported May 2
    		$0.88$0.83+6.02%Beat-
    Dec 16
    Reported Feb 2
    		$0.89$0.89+0.00%Beat-

    Dividends

    Dividend Metrics

    Forward Yield2.34%
    Forward Annual Dividend$3.40
    Payout Ratio42.01%
    FrequencyQuarterly
    Pay MonthsJan, Apr, Jul, Oct

    Growth

    3Y CAGR+5.42%
    5Y CAGR+5.75%
    MRK dividend history and ex-dividend datesRun MRK in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio45.28EV/EBITDA32.04x
    Price/FCF22.32xFCF Yield4.48%
    Profitability
    Profit Margin4.77%Operating Margin-0.24%
    ROE6.96%ROIC4.03%
    Financial Health
    Debt/Equity1.29xInterest CoverageN/A
    Current Ratio1.32xQuick Ratio1.10x
    Trading Statistics
    Beta0.22Avg Volume10.10M
    52-Week High$156.0052-Week Low$79.67

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$143.67
    SMA 20$145.80
    SMA 50$144.32
    SMA 200$123.67
    EMA 10$144.76
    EMA 20$144.98
    EMA 50$142.24
    EMA 200$124.47

    MACD

    Line: -0.00Signal: 0.13Hist: -0.14

    ADX

    ADX: 16.4+DI: 28.5-DI: 20.7

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down68.0
    PSAR$138.99

    Bollinger Bands

    Upper Band$151.93
    Lower Band$139.66
    %B Position842%(Upper)
    Band Width0.46

    RSI (14-Day)

    Neutral
    51.1

    Momentum Oscillators

    Stoch %K49.2
    Stoch %D46.5
    Williams %R-51.6
    ROC (10d)1.1%
    Momentum1.54
    CCI (20d)44.0
    MFI (14d)51.0

    Volatility Measures

    ATR (14d)$3.98(2.7%)
    StdDev (20d)3.07
    Hist Vol27.7%(Moderate)

    Volume Flow

    VWAP$147.54
    OBV357.2M
    AD Line-4.8B
    CMF (20d)-0.017

    Volume Metrics

    Avg Vol (20d)10.2M
    Vol Ratio1.4x
    VWMA (20d)$145.99

    Pivot Points

    R3$154.96
    R2$151.56
    R1$149.46
    Pivot Point$146.06
    S1$143.97
    S2$140.57
    S3$138.47

    Advanced Oscillators

    TSI-0.17
    Ultimate Osc49.4
    KST-13.96

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$16.61B$16.29B$16.40B$17.28B$15.81B$15.53B$15.62B$16.66B$16.11B$15.78B$14.63B$15.96B
    Cost of Revenue$4.39B$4.20B$5.55B$3.85B$3.56B$3.42B$3.83B$4.08B$3.75B$3.54B$3.91B$4.26B
    Gross Profit$12.21B$12.09B$10.85B$13.42B$12.25B$12.11B$11.80B$12.58B$12.37B$12.23B$10.72B$11.70B
    Operating Expenses$12.80B$15.49B$7.00B$6.91B$7.26B$6.24B$7.50B$8.65B$6.32B$6.60B$12.69B$5.95B
    R&D$9.74B$12.59B$3.89B$4.23B$4.05B$3.62B$4.58B$5.86B$3.50B$3.99B$9.63B$3.31B
    SG&A$2.90B$2.70B$2.90B$2.63B$2.65B$2.55B$2.86B$2.73B$2.74B$2.48B$2.80B$2.52B
    Operating Income$-584,000,000$-3,396,000,000$3.85B$6.51B$4.99B$5.87B$4.30B$3.93B$6.05B$5.64B$-1,967,000,000$5.75B
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$99.00M$138.00M$431.00M$0$0$0$129.00M$0$42.00M$0$79.00M$126.00M
    Income Before Tax$-683,000,000$-3,534,000,000$3.42B$6.75B$5.00B$5.90B$4.17B$4.09B$6.01B$5.67B$-2,046,000,000$5.62B
    Income Tax Expense$654.00M$709.00M$457.00M$958.00M$571.00M$818.00M$426.00M$929.00M$545.00M$903.00M$-820,000,000$870.00M
    Net Income$-1,337,000,000$-4,243,000,000$2.96B$5.79B$4.43B$5.08B$3.74B$3.16B$5.46B$4.77B$-1,226,000,000$4.75B
    EBITDA$900.00M$-2,022,000,000$5.89B$7.90B$6.12B$7.00B$5.37B$5.28B$7.14B$6.65B$-1,082,000,000$6.63B
    EBIT$-683,000,000$-3,534,000,000$3.42B$6.75B$5.00B$5.90B$4.17B$4.09B$6.01B$5.67B$-2,046,000,000$5.62B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    I Ranked SCHD's 98 Holdings for Dividend Growth and Total Return. The Biggest Ones Didn't Come Out on Top.

    SCHD's five largest - TXN, QCOM, PG, CVX, KO - are 21.7% of the fund; DGTR ranks them 43, 40, 53, 18, 52, so largest weights are not DGTR's top picks Only 23.5% of SCHD sits in DGTR's top 20 names, while 30.2% sits in DGTR's 16 lowest-ranked scored stocks...

    Glenn Ford
    •
    10/10/26
    •
    346
    Dividend Investing, Dividend Growth, Income Investing, ETFs
    Also mentions:
    TXNQCOMPGCVXKO

    Pfizer: The 6% Yield Hiding Behind a Post-Pandemic Hangover

    Pfizer trades at 9.6x forward earnings with 6.3% yield; non-COVID portfolio grew 6% operationally in 2025, but market still prices post-pandemic discount GAAP payout ratio of 98.8% is misleading; on adjusted EPS of $3.22...

    Glenn Ford
    •
    2/12/26
    •
    171
    Income Investing, value investing
    Also mentions:
    MRKBMYGILDABBV

    Ultra ZEUS: The Ultimate "Magic Money Machine" (22% Target Return with Ultra Low Volatility) For My Family's Needs For 2026

    GNG Research is built around a dream to democratize financial information and to create investing tools and automated systems that allow ANYONE to achieve their financial dreams. The Medallion Fund from Renaissance Tech shows the power of a well-designed algo fund...

    Adam Galas
    •
    1/6/26
    •
    1,466
    2026 Stock Picks, 2026 probable returns, value investing, Income, Value
    Also mentions:
    MRKMELIEPDCTASQQQ

    Government Contracts

    Gov Obligations (TTM)
    $5.15M
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    -96.7%
    Active Awards
    49
    New Awards (TTM)
    38
    Avg Remaining Term
    93.6 mo

    Top agency: Department of Health and Human Services at 75.3% of trailing twelve month obligations across 6 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26026F0282Department of Veterans AffairsDepartment of Veterans Affairs$342254Jun 1, 2026
    140F1G25P0056Department of the InteriorU.S. Fish and Wildlife Service$297003Aug 15, 2025
    140R3025P0053Department of the InteriorBureau of Reclamation$127600Sep 18, 2025
    140G0326P0069Department of the InteriorU.S. Geological Survey$122636Mar 16, 2026
    36C26126N0291Department of Veterans AffairsDepartment of Veterans Affairs$96218Jan 13, 2026
    140R4025P0100Department of the InteriorBureau of Reclamation$90955Sep 16, 2025
    140R2026P0003Department of the InteriorBureau of Reclamation$73669Mar 12, 2026
    36C26026F0280Department of Veterans AffairsDepartment of Veterans Affairs$42782May 4, 2026
    140F1G26P0027Department of the InteriorU.S. Fish and Wildlife Service$25967Jul 27, 2026
    140F1G25P0078Department of the InteriorU.S. Fish and Wildlife Service$24818Sep 10, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Moderna stock sinks as Wall Street turns cautious following blistering rally

    Moderna (MRNA) stock fell 9% due to investors taking profits and Wall Street analysts becoming cautious after a significant year-to-date rally of over 600%. Goldman Sachs, Morgan Stanley...

    Yahoo Finance•10/16/26•Somewhat-Bullish

    Three-year-old boy shows early improvement after receiving investigational brain tumor treatment NEO100 in Abu Dhabi

    NeOnc Technologies reported early clinical improvement in a three-year-old boy with an aggressive brain tumor, who received the investigational intranasal treatment NEO100 under compassionate use in Abu Dhabi. While...

    Pluang•10/16/26•Somewhat-Bullish

    Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up

    The weight-loss drug market is projected to reach $100 billion in annual sales within the next decade, leading to intense competition among biotech and pharmaceutical companies. Major players like Novo Nordisk and Eli...

    KSL News•10/16/26•Somewhat-Bullish

    8,527 Shares of Merck & Co., Inc. $MRK Acquired by Neumann Capital Management LLC

    Neumann Capital Management LLC acquired a new position of 8,527 shares in Merck & Co., Inc. (NYSE:MRK) during the third quarter...

    MarketBeat•10/16/26•Somewhat-Bullish

    Milestone Asset Management LLC Sells 9,248 Shares of Merck & Co., Inc. $MRK

    Milestone Asset Management LLC has reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 54.5%, selling 9,248 shares and retaining 7,709 shares valued at approximately $1.12 million. Despite this...

    MarketBeat•10/16/26•Neutral

    MRK Valuation and Fair Value

    P/E
    45.3x
    Forward P/E
    15.3x
    EV/EBITDA
    32.0x
    P/FCF
    22.3x
    PEG
    2.7x
    P/B
    8.6x
    See GNG's fair value

    MRK Profitability: Margins, ROIC and FCF

    Gross margin
    73.0%
    Operating margin
    -0.2%
    Net margin
    4.8%
    ROIC
    4.0%
    ROE
    7.0%
    FCF margin
    24.1%
    FCF yield
    4.5%

    MRK Competitors

    CompanyTicker
    AbbVie IncABBV
    UnitedHealth Group IncorporatedUNH
    Johnson & JohnsonJNJ
    Novartis AG ADRNVS
    Eli Lilly and CompanyLLY
    AstraZeneca PLCAZN
    Thermo Fisher Scientific IncTMO
    Amgen IncAMGN

    Sector: Healthcare

    MRK Analyst Ratings

    Consensus
    Buy
    Analysts
    27
    Strong Buy
    5
    Buy
    14
    Hold
    8
    Sell
    0
    Strong Sell
    0

    MRK Bull Case vs Bear Case

    Bull case

    • MRK converts 24.1% of revenue into free cash flow.
    • MRK beat EPS estimates in 87.5% of its last 8 reported quarters.
    • 70.4% of MRK's analyst ratings are Buy or Strong Buy.

    Bear case

    • MRK trades at 45.3x trailing earnings.

    MRK Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    10.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $2.13
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 1 down

    MRK Dividend

    Forward yield
    2.3%
    Payout ratio
    42.0%
    3Y DPS growth
    5.4%
    5Y DPS growth
    5.8%
    Pay months
    Jan, Apr, Jul, Oct
    MRK dividend history

    Frequently Asked Questions About MRK

    What is MRK's current dividend yield?

    Merck & Company Inc (MRK) has a forward dividend yield of 2.34%.

    Does MRK pay dividends?

    Yes, Merck & Company Inc pays dividends with a forward dividend yield of 2.34%.

    What is MRK's P/E ratio?

    Merck & Company Inc has a price-to-earnings (P/E) ratio of 45.28.

    What is MRK's market cap?

    Merck & Company Inc (MRK) has a market capitalization of $363.59B with a current stock price of $145.35.

    Related stocks

    Sector: Healthcare

    All stocks starting with M

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In